MCID: STM006
MIFTS: 48

Stomach Disease

Categories: Gastrointestinal diseases

Aliases & Classifications for Stomach Disease

MalaCards integrated aliases for Stomach Disease:

Name: Stomach Disease 12 15 17
Stomach Diseases 43 71
Gastropathy 12 54
Stomach Disorders 42
Stomach Disorder 12
Gastric Disorder 54
Gastric Disease 12

Classifications:



External Ids:

Disease Ontology 12 DOID:76
MeSH 43 D013272
NCIt 49 C26886
SNOMED-CT 67 29384001
UMLS 71 C0038354

Summaries for Stomach Disease

MedlinePlus : 42 Your stomach is an organ between your esophagus and small intestine. It is where digestion of protein begins. The stomach has three tasks. It stores swallowed food. It mixes the food with stomach acids. Then it sends the mixture on to the small intestine. Most people have a problem with their stomach at one time or another. Indigestion and heartburn are common problems. You can relieve some stomach problems with over-the-counter medicines and lifestyle changes, such as avoiding fatty foods or eating more slowly. Other problems like peptic ulcers or GERD require medical attention. You should see a doctor if you have any of the following: Blood when you have a bowel movement Severe abdominal pain Heartburn not relieved by antacids Unintended weight loss Ongoing vomiting or diarrhea NIH: National Institute of Diabetes and Digestive and Kidney Diseases

MalaCards based summary : Stomach Disease, also known as stomach diseases, is related to functional gastric disease and gastritis, and has symptoms including nausea and vomiting, constipation and abdominal pain. An important gene associated with Stomach Disease is DDX21 (DExD-Box Helicase 21), and among its related pathways/superpathways are MicroRNAs in cancer and Angiogenesis (CST). The drugs Propofol and Midazolam have been mentioned in the context of this disorder. Affiliated tissues include stomach, kidney and liver.

Disease Ontology : 12 A gastrointestinal system disease that is located in the stomach.

Wikipedia : 74 Stomach diseases include gastritis, gastroparesis, Crohn's disease and various... more...

Related Diseases for Stomach Disease

Diseases related to Stomach Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 362)
# Related Disease Score Top Affiliating Genes
1 functional gastric disease 34.4 PTGS2 HRH2 GHRL
2 gastritis 33.1 PTGS2 PTGS1 HRH2 GHRL
3 active peptic ulcer disease 31.6 PTGS2 PTGS1 HRH2
4 peptic ulcer disease 31.3 PTGS2 PTGS1 HRH2 HDC GHRL
5 gastric ulcer 31.2 PTGS2 PTGS1 MMP7 HRH2
6 gastrointestinal system disease 30.9 MIR9-1 MIR30A MIR21 MIR20A MIR199A1 MIR196A1
7 gastrointestinal ulceration, recurrent, with dysfunctional platelets 30.9 PTGS2 PTGS1 HRH2
8 vascular disease 30.8 TIMP1 PTGS2 PTGS1 MIR21 MIR199A1 MIR145
9 gastroesophageal reflux 30.8 PTGS2 PTGS1 HRH2 GHRL
10 gastric cancer 30.8 TIMP1 PTGS2 MMP7 MIR9-1 MIR21 MIR20A
11 diabetes mellitus, noninsulin-dependent 30.8 PTGS2 MIR30A MIR21 MIR199A1 MIR196A1 MIR17
12 leukemia, chronic myeloid 30.8 MIR9-1 MIR20A MIR196A1 MIR17 MIR125A
13 esophageal cancer 30.7 TIMP1 PTGS2 MMP7 MIR9-1 MIR30A MIR21
14 leukemia, acute lymphoblastic 30.7 MIR9-1 MIR21 MIR196A1 MIR17 MIR125A
15 colorectal adenoma 30.5 PTGS2 PTGS1 MMP7 MIR21 MIR17
16 large intestine cancer 30.3 MIR9-1 MIR30A MIR21 MIR20A MIR199A1 MIR196A1
17 periodontitis 30.2 TIMP1 PTGS2 MIR21
18 peptic esophagitis 29.9 PTGS2 HRH2
19 non-hypoproteinemic hypertrophic gastropathy 12.4
20 gastritis, familial giant hypertrophic 11.8
21 esophagus adenocarcinoma 10.8 PTGS2 MIR21 MIR196A1 MIR145 MIR143
22 gastrointestinal system benign neoplasm 10.8 PTGS2 MIR21 MIR20A MIR199A1 MIR196A1 MIR17
23 cell type benign neoplasm 10.8 PTGS2 MIR21 MIR199A1 MIR196A1 MIR17 MIR143
24 intestinal benign neoplasm 10.8 PTGS2 MIR21 MIR20A MIR199A1 MIR17 MIR143
25 endocrine organ benign neoplasm 10.8 MIR21 MIR199A1 MIR196A1 MIR17
26 mature b-cell neoplasm 10.8 MIR9-1 MIR199A1 MIR196A1 MIR17
27 tongue disease 10.8 MIR30A MIR21 MIR199A1 MIR196A1 MIR17 MIR145
28 retinal cancer 10.8 MIR9-1 MIR199A1 MIR196A1 MIR17 MIR125A
29 muscle cancer 10.8 MIR9-1 MIR199A1 MIR196A1 MIR143
30 larynx cancer 10.8 MIR21 MIR196A1 MIR17 MIR143 MIR129-1
31 ovarian serous carcinoma 10.8 MIR21 MIR20A MIR199A1 MIR145 MIR143 MIR125A
32 malignant ovarian surface epithelial-stromal neoplasm 10.8 MIR30A MIR21 MIR199A1 MIR196A1 MIR17 MIR145
33 ocular cancer 10.8 MIR9-1 MIR199A1 MIR196A1 MIR17 MIR125A
34 rectum cancer 10.8 MMP7 MIR21 MIR20A MIR196A1 MIR17 MIR145
35 ovary epithelial cancer 10.8 MIR30A MIR21 MIR199A1 MIR196A1 MIR17 MIR145
36 laryngeal disease 10.8 MIR21 MIR20A MIR196A1 MIR17 MIR149 MIR143
37 renal fibrosis 10.8 TIMP1 MIR21 MIR199A1 MIR196A1
38 bile duct adenocarcinoma 10.8 MIR9-1 MIR30A MIR21 MIR199A1 MIR17 MIR125A
39 bone inflammation disease 10.8 PTGS2 MIR30A MIR21 MIR199A1 MIR196A1 MIR17
40 thyroid gland papillary carcinoma 10.8 MIR9-1 MIR30A MIR199A1 MIR17 MIR125A
41 gallbladder disease 10.8 MIR199A1 MIR17 MIR145 MIR143
42 retinal vascular disease 10.8 MIR30A MIR21 MIR20A MIR199A1
43 bone marrow cancer 10.8 MIR9-1 MIR30A MIR21 MIR199A1 MIR196A1 MIR17
44 pancreatic ductal adenocarcinoma 10.8 MIR21 MIR199A1 MIR196A1 MIR145 MIR143
45 chromosomal disease 10.8 MIR9-1 MIR196A1 MIR17 GHRL
46 bile duct disease 10.8 MIR9-1 MIR30A MIR199A1 MIR196A1 MIR17 MIR145
47 overnutrition 10.8 MIR9-1 MIR21 MIR199A1 MIR196A1 MIR17 MIR143
48 diffuse large b-cell lymphoma 10.8 MIR21 MIR199A1 MIR17 MIR149 MIR145 MIR143
49 pulmonary fibrosis, idiopathic 10.8 TIMP1 MMP7 MIR21 MIR199A1 MIR196A1
50 mouth disease 10.8 MIR9-1 MIR21 MIR199A1 MIR196A1 MIR17 MIR145

Graphical network of the top 20 diseases related to Stomach Disease:



Diseases related to Stomach Disease

Symptoms & Phenotypes for Stomach Disease

UMLS symptoms related to Stomach Disease:


nausea and vomiting, constipation, abdominal pain, diarrhea, icterus, signs and symptoms, digestive, dyspepsia, heartburn, gastrointestinal gas, stomach ache

Drugs & Therapeutics for Stomach Disease

Drugs for Stomach Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 131)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Propofol Approved, Investigational, Vet_approved Phase 4 2078-54-8 4943
2
Midazolam Approved, Illicit Phase 4 59467-70-8 4192
3
Epinephrine Approved, Vet_approved Phase 4 51-43-4 5816
4
Racepinephrine Approved Phase 4 329-65-7 838
5
Carvedilol Approved, Investigational Phase 4 72956-09-3 2585
6
Miconazole Approved, Investigational, Vet_approved Phase 4 22916-47-8 4189
7
Tacrolimus Approved, Investigational Phase 4 104987-11-3 445643 439492 6473866
8
Prednisone Approved, Vet_approved Phase 4 53-03-2 5865
9
Omeprazole Approved, Investigational, Vet_approved Phase 4 73590-58-6 4594
10
Pantoprazole Approved Phase 4 102625-70-7 4679
11
Esomeprazole Approved, Investigational Phase 4 161796-78-7, 161973-10-0, 119141-88-7 9568614 4594
12
Calcium Approved, Nutraceutical Phase 4 7440-70-2 271
13 Rebamipide Investigational Phase 4 90098-04-7
14 Adrenergic Agents Phase 4
15 Autonomic Agents Phase 4
16 Anti-Anxiety Agents Phase 4
17 Tranquilizing Agents Phase 4
18 Hypnotics and Sedatives Phase 4
19 Anesthetics Phase 4
20 GABA Agents Phase 4
21 Anesthetics, General Phase 4
22 Adjuvants, Anesthesia Phase 4
23 Psychotropic Drugs Phase 4
24 Anesthetics, Intravenous Phase 4
25 Central Nervous System Depressants Phase 4
26 GABA Modulators Phase 4
27 Sympathomimetics Phase 4
28 Adrenergic Agonists Phase 4
29 Epinephryl borate Phase 4
30 Hemostatics Phase 4
31 Anti-Asthmatic Agents Phase 4
32 Adrenergic beta-Agonists Phase 4
33 Vasoconstrictor Agents Phase 4
34 Bronchodilator Agents Phase 4
35 Mydriatics Phase 4
36 Dermatologic Agents Phase 4
37 Hormones Phase 4
38 Adrenergic alpha-Antagonists Phase 4
39 calcium channel blockers Phase 4
40 Calcium, Dietary Phase 4
41 Antirheumatic Agents Phase 4
42 Immunologic Factors Phase 4
43 Acidophilus Phase 4
44 Bifidobacterium Phase 4
45 Immunosuppressive Agents Phase 4
46 Antifungal Agents Phase 4
47 Cyclosporins Phase 4
48 Calcineurin Inhibitors Phase 4
49 Pharmaceutical Solutions Phase 4
50 Neurotransmitter Agents Phase 4

Interventional clinical trials:

(show top 50) (show all 75)
# Name Status NCT ID Phase Drugs
1 Randomized Controlled Trial Comparing Effects of Sedation for Upper Gastrointestinal Endoscopy With Propofol Versus Midazolam on Psychometric Tests and Critical Flicker Frequency in Cirrhotics Unknown status NCT01356121 Phase 4 Propofol;Midazolam
2 Prospective, Randomized Trial of Hemospray Plus Epinephrine Injection Versus Endoscopic Hemoclip Plus Epinephrine Injection in Nonvariceal Upper Gastrointestinal Bleeding Unknown status NCT02537353 Phase 4 Hemospray;Adrenaline
3 Randomized Double-Blind Clinical Trial of Rebamipide vs Esomeprazole in the Treatment of NSAID-induced Gastropathy Completed NCT00641004 Phase 4 Rebamipide and Esomeprazole
4 Multicenter, Randomized, Double-blind, Placebo-controlled Study on the Effectiveness of Treatment With Beta-blockers to Prevent Decompensation of Cirrhosis With Portal Hypertension Completed NCT01059396 Phase 4 propranolol;carvedilol;placebo
5 Effect of Early Oral Triple Viable Bifidobacterium Intestinal Flora in Preterm Completed NCT02060084 Phase 4 a control group;a probiotic-supplemented group
6 Randomized Open Label Study Comparing the Metabolic Control of Kidney Transplant Recipients With Type 2 Diabetes Receiving Either Prograf or Neoral as Part of a ATG Induction, Prednisone Free and Monitored MMF Immunosuppressive Regimen. Completed NCT00296296 Phase 4 Cyclosporin;Tacrolimus
7 Omentopexy With Glubran®2 for Reducing Complications After Laparoscopic Sleeve Gastrectomy: Results of a Prospective Study. Completed NCT03833232 Phase 4
8 Study of the Effect of PROGRESSive Withdrawal Esomeprazole of on Acid-related Symptoms, PROGRESS Study A Randomized, Placebo-controlled, Double Blinded Study Recruiting NCT02476097 Phase 4 Esomeprazole: Nexium® 20mg, Astra Zeneca;Placebo
9 Role of Scheduled Intravenous Acetaminophen for Postoperative Pain Management in an Enhanced Recovery After Surgery (ERAS) Population: A Prospective, Randomized, Double-Blind and Placebo-Controlled Clinical Trial Active, not recruiting NCT03198871 Phase 4 Acetaminophen Injectable Product;Sodium Chloride 0.9%, Intravenous
10 Phase IV, Multicenter, Open Label, Randomized Study in Parallel Groups To Assess The Efficacy And Safety Of Bismuth Tripotassium Dicitrate (De-Nol®) In Combination With Pantoprazole And Pantoprazole Monotherapy In Treatment Of Patients With NSAID Induced Gastropathy Terminated NCT02788123 Phase 4 bismuth tripotassium dicitrate;pantoprazole
11 Double-Blind, Randomized, Placebo-Controlled Trial To Assess Efficacy And Safety Of R051619 (Cisapride 10 mg q.i.d.) Versus Placebo For The Improvement Of Symptoms Associated With Exacerbations Of Idiopathic Gastroparesis, After Failure Of Other Treatment Options Terminated NCT01281540 Phase 4 Cisapride;Placebo
12 Effects of Esomeprazole Magnesium on Gastric Free Radical Production and Total Antioxidant Capacity in Dyspeptic Patients Receiving Non-Steroidal Anti-Inflammatory Drugs Terminated NCT00443963 Phase 4 Esomeprazole Magnesium
13 Double-Blind, Randomized, Placebo-Controlled Trial to Assess Efficacy and Safety of R051619 (Cisapride 10 mg Q.I.D.) Versus Placebo for the Improvement of Symptoms Associated With Exacerbations of Gastroparesis, After Failure of Other Treatments, in Patients With Diabetes Mellitus Terminated NCT01286090 Phase 4 Cisapride;Placebo
14 Daily Tadalafil and Gastric Emptying Time in Diabetic Gastroparesis Withdrawn NCT01326117 Phase 4 tadalafil
15 Phase 3 Companion Study of Intranasal Metoclopramide in Men With Symptomatic Diabetic Gastroparesis Completed NCT02025751 Phase 3 Metoclopramide Nasal Spray;Placebo Nasal Spray
16 Phase 3 Study of Intranasal Metoclopramide in Women With Symptomatic Diabetic Gastroparesis Completed NCT02025725 Phase 3 Metoclopramide Nasal Spray;Placebo Nasal Spray
17 Double-Blind Placebo-Controlled Cross-Over Design With Wash-Out for Temporary Gastric Electrical Stimulation for Drug Refractory Gastroparesis Completed NCT00432835 Phase 3
18 Phase III General Clinical Study of NPO-11 in Patients Undergoing Gastric Endoscopy (Open-label Study) Completed NCT00745459 Phase 3 NPO-11
19 Magnetic-controlled Capsule Endoscopy vs. Gastroscopy for Detection of Gastric Diseases: A Prospective Self-controlled Comparative Multicenter Trial Completed NCT02219529 Phase 3
20 Phase III Controlled Clinical Study of NPO-11 in Patients Undergoing Gastric Endoscopy (Randomized, Double-blind, Parallel-assignment , Placebo-controlled Study) Completed NCT00742599 Phase 3 NPO-11;Placebo
21 A Randomized, Double-blind, Multi-center Phase III Study Comparing Everolimus (RAD001) Plus Best Supportive Care Versus Placebo Plus Best Supportive Care in Patients With Advanced Gastric Cancer After Progression on 1 or 2 Prior Systemic Chemotherapy Completed NCT00879333 Phase 3 Everolimus;Everolimus placebo;Best Supportive Care (BSC)
22 Effect of Oral Phloroglucin (Flospan®) as Premedication of Non-sedative Diagnostic Esophagogastroduodenoscopy: Single Center, Prospective, Double Blinded, Randomized Controlled Trial Completed NCT03342118 Phase 3 Phloroglucin(Flospan®);Normal saline
23 Proton Pump Inhibitor Plus Propranolol Versus Proton Pump Inhibitor Alone on Peptic Ulcer Healing in Patients With Liver Cirrhosis: a Randomized Trail Recruiting NCT04140591 Phase 2, Phase 3 Proton-pump inhibitor;Propranolol+Proton-pump inhibitor
24 A Phase III Study of Comparing the Maintenance Treatment of Apatinib, Capecitabine and Observation After First-line Therapy in Advanced Gastric Cancer Not yet recruiting NCT03889626 Phase 3 Apatinib;Capecitabine
25 Gastric Preparation of Magnetic-controlled Capsule Endoscopy: A Prospective, Single Blinded and Randomized Controlled Trial Unknown status NCT02846155 Phase 2 simethicone;simethicone combined with pronase
26 A Single-arm, Multi-center, Phase II Study to Evaluate Efficacy and Safety of Dovitinib (TKI258) in Adult Patients With Advanced Scirrhous Gastric Carcinoma That Have Progressed After One or Two Prior Systemic Treatments Completed NCT01576380 Phase 2 TKI258
27 A Double-blind Randomised Controlled Trial on Flufenamic Acid for Hospitalised Influenza Infection Recruiting NCT03238612 Phase 2 FFA, clarithromycin, oseltamivir;Oseltamivir alone
28 Effect of Ocoxin®-Viusid® Nutritional Supplement on the Quality of Life of Patients With Advanced Stomach Cancer and Esophagogastric Junction. Phase II Clinical Trial. Recruiting NCT03549494 Phase 2
29 Pembrolizumab, Radiotherapy, and Chemotherapy in Neoadjuvant Treatment of Malignant Esophago-gastric Diseases (PROCEED) Recruiting NCT03064490 Phase 2 Pembrolizumab
30 the Effect of Daily Use of Proton Pump Inhibitors for One Month on Renal Function Not yet recruiting NCT03910647 Phase 2 pantoprazole
31 Effect of Proton Pump Inhibitor of Daily Use for One Month on Kidney Function Test Not yet recruiting NCT04022837 Phase 2 Pantoprazole 40mg
32 Functional Consequences and Therapeutic Intervention in Hampered Production of Cysteine, Glutathione and Taurine in Classical Homocystinuria Not yet recruiting NCT04015557 Phase 1, Phase 2 Acetaminophen;N-acetylcysteine
33 Assessment of the Effect of Tegaserod (2 mg Tid and 6 mg Tid) on Dyspeptic Symptoms in Diabetic Patients With Symptoms of Diabetic Gastropathy Terminated NCT00142974 Phase 2 Tegaserod
34 A Phase 2, Open-label Evaluation of CRS-207 and Pembrolizumab in Adults With Recurrent or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinomas Terminated NCT03122548 Phase 2
35 A Multicenter, Open-label, Single and Multiple Dose Pharmacokinetic Study of IV Pantoprazole in Preterm Infants and Infants 0-11 Months With a Clinical Diagnosis of Gastroesophageal Reflux Disease (GERD) or the Need for Acid Suppression Completed NCT00744419 Phase 1 pantoprazole
36 A Phase 1, Multicenter, Open-label, Multiple Dose-escalation Study of ARX788, Intravenously Administered as a Single Agent in Subjects With Advanced Cancers With HER2 Expression Recruiting NCT03255070 Phase 1 ARX788
37 Indications and Outcomes of Gastrointestinal Endoscopic Ultrasound in Tanta-Egypt: Initial Experience. Unknown status NCT03267355
38 CMV Criteria in the Detection of Gastric Diseases Using Linked Color Imaging Unknown status NCT03092414
39 Gastric Emptying: in Vivo Studies in Healthy Volunteers (Using Scrambled Egg and Porridge) to Determine Reliable Normal Ranges Unknown status NCT02994472
40 Evaluation of Blood Ammonia Level as a Non Invasive Predictor for Presence of Gastroesophageal Varices and Risk of Bleeding Unknown status NCT03212872
41 An Investigational New Drug Program for the Use of Domperidone in the Treatment of Refractory Gastroesophageal Reflux Disease and Other Gastrointestinal Motility Disorders Unknown status NCT00777439 Domperidone
42 Comparison of Effectiveness of "Sekanjabin e Safarjali" (Quince Oxymel), Propranolol and Placebo in the Prevention of Migraine Attacks in Patients With Simultaneous Upper Gastrointestinal Dysfunction Unknown status NCT02179775 propranolol;Quince's oxymel;placebo
43 Screening for Stomach Diseases and Colorectal Neoplasms With the Fecal Testing: a Population-based Randomized Study Unknown status NCT01741363
44 Transoral Removal of Specimen During Laparoscopic Gastric Resection Completed NCT04111393
45 Optimization of Simethicone Administration Strategy Before Esophagogastroscopy Completed NCT03776916
46 Safety and Feasibility of TachoSil®: Application on Esophageal Anastomoses Completed NCT02105506 Tachosil patch
47 Has the Quota of Signet Ring Cells an Influence on Prognosis and Treatment Strategy in the Upper GI Tract Adenocarcinomas? Completed NCT01249859
48 Enteral Nutrition as Stress Ulcer Prophylaxis in Critically Ill Patients. Prospective, Double-blind, Randomized, Placebo-controlled Study. Completed NCT01477320 Pantoprazole 40 mg IV daily and tube feed.
49 A Pilot Study to Investigate Whether Intragastric Pressure During Food Intake Can be Measured Using an Intragastric Bag in Healthy Volunteers Completed NCT03500887
50 Risk Factors for Gastric Disease in Pediatric H. Pylori Completed NCT00212225

Search NIH Clinical Center for Stomach Disease

Cochrane evidence based reviews: stomach diseases

Genetic Tests for Stomach Disease

Anatomical Context for Stomach Disease

The Foundational Model of Anatomy Ontology organs/tissues related to Stomach Disease:

19
Stomach

MalaCards organs/tissues related to Stomach Disease:

40
Kidney, Liver, Bone, Small Intestine, Testes, Thyroid, Colon

Publications for Stomach Disease

Articles related to Stomach Disease:

(show top 50) (show all 438)
# Title Authors PMID Year
1
Comparative study of magnifying narrow-band imaging and conventional white light endoscopy in the diagnosis of Helicobacter pylori status after eradication therapy. 42
31725612 2019
2
Median Arcuate Ligament Syndrome and Its Associated Conditions. 42
31657316 2019
3
Acupoint catgut embedding for diabetic gastroparesis: A protocol of systematic review. 42
31651905 2019
4
[Stomach disease and ghrelin]. 54 61
15506414 2004
5
High-Salt Diet-Induced Gastritis in C57BL/6 Mice is Associated with Microbial Dysbiosis and Alleviated by a Buckwheat Diet. 61
32032975 2020
6
GCdiscrimination: identification of gastric cancer based on a milliliter of blood. 61
32010933 2020
7
Laser-induced fluorescence diagnosis of stomach tumor. 61
31953738 2020
8
Initiatives for a Healthy Stomach. 61
31776804 2019
9
Significant of adiponectin in gastropathy: Case-controlled study. 61
31641495 2019
10
[Professor CHU Hao-ran's experience of acupuncture and moxibustion of regulating spleen-stomach and differentiating meridians-collaterals]. 61
31724359 2019
11
Two novel transcriptional reporter systems for monitoring Helicobacter pylori stress responses. 61
31669286 2019
12
Helicobacter pylori infection and the risk of colorectal carcinoma: a systematic review and meta-analysis. 61
31368293 2019
13
History of gastroesophageal reflux disease in patients with suspected coronary artery disease. 61
30993440 2019
14
METALLOTHIONEIN-2A (RS1610216&RS28366003) GENE POLYMORPHISMS AND THE RISK OF STOMACH ADENOCARCINOMA. 61
31721970 2019
15
Evaluation of hepatotoxicity potential of a potent traditional Tibetan medicine Zuotai. 61
30580024 2019
16
[Risk factors of oral Helicobacter pylori infection among children in two kindergartens in Suzhou and the effects of oral cleaning on reducing oral Helicobacter pylori infection]. 61
30854823 2019
17
Investigation on correlations of serum IL-26 with diagnosis and staging of gastric cancer. 61
30941972 2019
18
[Effect of modified Zhengqi Powder in treating chronic gastritis and on patients' life quality and inflammatory factors]. 61
30868830 2019
19
N-Alkylamides from Piper longum L. and their stimulative effects on the melanin content and tyrosinase activity in B16 melanoma cells. 61
30623685 2019
20
A Clinical Trial on Oral H. pylori Infection of Preschool Children. 61
30610045 2018
21
[Analysis on medication regularity and action mechanism of Tibetan medicine in treatment of spleen and stomach diseases based on data mining and integrated pharmacology]. 61
30200743 2018
22
Pistacia atlantica Desf. A review of its traditional uses, phytochemicals and pharmacology. 61
30364651 2018
23
Effect of Pistacia atlantica kurdica gum on diabetic gastroparesis symptoms: a randomized, triple-blind placebo-controlled clinical trial. 61
30128090 2018
24
Calycophyllum spruceanum BENTH ameliorates acute inflammation in mice. 61
29567276 2018
25
[Research progress of Tibetan medicine "Zha-xun"]. 61
29751700 2018
26
Levels of malondialdehyde in the gastric juice: Its association with Helicobacter pylori infection and stomach diseases. 61
29315971 2018
27
Dihydroorotate Dehydrogenase as a Target for the Development of Novel Helicobacter pylori-Specific Antimicrobials. 61
29491257 2018
28
In situ quantification and evaluation of ClO-/H2S homeostasis in inflammatory gastric tissue by applying a rationally designed dual-response fluorescence probe featuring a novel H+-activated mechanism. 61
28394381 2017
29
Application of Micellar Extraction for Isolation of Famotidine from Aqueous Samples Prior to its Chromatographic Determination. 61
29200812 2017
30
[Expressions of MMP-7 and TIMP-1 in Chronic Stomach Disease Patients with Different Syndromes of Chinese Medicine]. 61
30695426 2017
31
Serum Pepsinogen Levels Are Correlated With Age, Sex and the Level of Helicobacter pylori Infection in Healthy Individuals. 61
27865295 2016
32
Image enhancement based on in vivo hyperspectral gastroscopic images: a case study. 61
27206742 2016
33
Trichloromethane fraction of Incarvillea compacta induces lytic cytotoxicity and apoptosis in Epstein-Barr virus-positive gastric cancer AGS cells. 61
27595569 2016
34
Ethnobotany, chemical constituents and biological activities of the flowers of Hydnora abyssinica A.Br. (Hydnoraceae). 61
27209704 2016
35
Changes in gastric microbiota induced by Helicobacter pylori infection and preventive effects of Lactobacillus plantarum ZDY 2013 against such infection. 61
26709179 2016
36
A large randomised controlled intervention trial to prevent gastric cancer by eradication of Helicobacter pylori in Linqu County, China: baseline results and factors affecting the eradication. 61
25986943 2016
37
Effect of propolis in gastric disorders: inhibition studies on the growth of Helicobacter pylori and production of its urease. 61
27233102 2016
38
[Midnight-noon ebb-flow acupuncture at stomach meridian of foot-yangming: a fMRI study]. 61
26964172 2015
39
Alterations in Th17 and the Respective Cytokine Levels in Helicobacter pylori-Induced Stomach Diseases. 61
25908492 2015
40
Prevalence of Chronic Disabling Noncancer Pain and Associated Demographic and Medical Variables: A Cross-Sectional Survey in the General German Population. 61
25411861 2015
41
Detection of oral Helicobacter Pylori infection using saliva test cassette. 61
26649012 2015
42
Generation of stomach tissue from mouse embryonic stem cells. 61
26192439 2015
43
The incidence of acute gastrointestinal illness in Sweden. 61
25969165 2015
44
PERIODONTAL POCKETS AS A RESERVOIR OF HELICOBACTER PYLORI CAUSING RELAPSE OF GASTRIC ULCER: A REVIEW OF THE LITERATURE. 61
26511191 2015
45
The human gastric microbiota: Is it time to rethink the pathogenesis of stomach diseases? 61
26137299 2015
46
Evaluation of bile reflux in HIDA images based on fluid mechanics. 61
25754361 2015
47
Evaluation of the medicinal properties of Cyrtocarpa procera Kunth fruit extracts. 61
25887560 2015
48
Antimicrobial activity, toxicity and selectivity index of two biflavonoids and a flavone isolated from Podocarpus henkelii (Podocarpaceae) leaves. 61
25293523 2014
49
Effects of Thymus hirtus sp. algeriensis Boiss. et Reut. (Lamiaceae) essential oil on healing gastric ulcers according to sex. 61
25159191 2014
50
Microbiota in the stomach: new insights. 61
24245792 2014

Variations for Stomach Disease

Expression for Stomach Disease

Search GEO for disease gene expression data for Stomach Disease.

Pathways for Stomach Disease

GO Terms for Stomach Disease

Cellular components related to Stomach Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.32 TIMP1 MMP7 MIR30A MIR21 MIR20A MIR199A1

Biological processes related to Stomach Disease according to GeneCards Suite gene sharing:

(show all 24)
# Name GO ID Score Top Affiliating Genes
1 negative regulation of apoptotic process GO:0043066 9.97 TIMP1 PTGS2 MIR30A MIR21 GHRL
2 negative regulation of gene expression GO:0010629 9.88 MIR21 MIR20A MIR17 MIR125A
3 positive regulation of angiogenesis GO:0045766 9.8 MIR30A MIR21 MIR20A MIR199A1 MIR143
4 negative regulation of angiogenesis GO:0016525 9.72 MIR21 MIR145 MIR143 MIR125A GHRL
5 positive regulation of vascular smooth muscle cell proliferation GO:1904707 9.7 MIR21 MIR20A MIR17
6 positive regulation of vascular associated smooth muscle cell migration GO:1904754 9.65 MIR21 MIR20A MIR143
7 negative regulation of stress fiber assembly GO:0051497 9.63 MIR21 MIR20A MIR149
8 negative regulation of cardiac muscle hypertrophy GO:0010614 9.62 MIR21 MIR145
9 regulation of smooth muscle contraction GO:0006940 9.61 MIR145 MIR143
10 negative regulation of low-density lipoprotein particle clearance GO:0010989 9.61 MIR199A1 MIR17
11 negative regulation of tumor necrosis factor secretion GO:1904468 9.6 MIR149 GHRL
12 prostaglandin biosynthetic process GO:0001516 9.59 PTGS2 PTGS1
13 cyclooxygenase pathway GO:0019371 9.57 PTGS2 PTGS1
14 positive regulation of metalloendopeptidase activity GO:1904685 9.56 MIR21 MIR17
15 negative regulation of cardiac muscle cell apoptotic process GO:0010667 9.56 MIR21 MIR20A MIR199A1 MIR145
16 angiotensin-activated signaling pathway GO:0038166 9.55 MIR145 MIR143
17 negative regulation of vascular associated smooth muscle cell apoptotic process GO:1905460 9.54 MIR21 MIR17
18 positive regulation of cardiac muscle hypertrophy in response to stress GO:1903244 9.54 MIR20A MIR199A1 MIR17
19 aorta smooth muscle tissue morphogenesis GO:0060414 9.51 MIR145 MIR143
20 regulation of phenotypic switching GO:1900239 9.49 MIR145 MIR143
21 establishment or maintenance of cell type involved in phenotypic switching GO:0044663 9.43 MIR145 MIR143
22 miRNA mediated inhibition of translation GO:0035278 9.43 MIR9-1 MIR30A MIR21 MIR20A MIR17 MIR145
23 gene silencing by miRNA GO:0035195 9.4 MIR9-1 MIR30A MIR21 MIR20A MIR199A1 MIR196A1
24 positive regulation of pulmonary blood vessel remodeling GO:1905111 9.33 MIR20A MIR17 MIR143

Molecular functions related to Stomach Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 mRNA binding involved in posttranscriptional gene silencing GO:1903231 9.4 MIR9-1 MIR30A MIR21 MIR20A MIR199A1 MIR196A1
2 RNA polymerase II complex binding GO:0000993 9.33 MIR20A MIR145 MIR125A
3 prostaglandin-endoperoxide synthase activity GO:0004666 8.96 PTGS2 PTGS1

Sources for Stomach Disease

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....